Why patients with Alzheimer’s disease may show increased sensitivity to tropicamide eye drops: role of locus coeruleus
Why patients with Alzheimer’s disease may show increased sensitivity to tropicamide eye drops: role of locus coeruleus
Rationale: patients suffering from Alzheimer’s disease (AD) may show increased sensitivity to tropicamide, a muscarinic cholinoceptor antagonist. AD is associated with a severe loss of noradrenergic neurones in the locus coeruleus (LC), which can be “switched off” experimentally by the ?2-adrenoceptor agonist clonidine. The possibility arises that increased pupillary sensitivity to tropicamide in AD may be due to diminished LC activity.
Objective: to examine the hypothesis that clonidine may potentiate tropicamide-evoked mydriasis.
Materials and methods: sixteen healthy male volunteers participated in two experimental sessions (0.2 mg clonidine or placebo) conducted 1 week apart. In each session tropicamide (0.01% 10 ?l×2) was applied to the left eye and artificial tear (10 ?l×2) was applied to the right eye. Pupillary functions (resting pupil diameter and light and darkness reflexes), alertness and non-pupillary autonomic functions (blood pressure, heart rate, core temperature and salivary output) were measured. Data were analysed by ANOVA, with multiple comparisons.
Results: tropicamide increased resting pupil diameter, velocity and amplitude of the darkness reflex response, and decreased recovery time of the light reflex response. Clonidine affected all these pupillary measures in the opposite direction with the exception of the recovery time. The mydriatic response to tropicamide was potentiated by pre-treatment with clonidine. Clonidine reduced critical flicker fusion frequency, subjective alertness, blood pressure, salivation and temperature.
Conclusions: the potentiation of tropicamide-evoked pupil dilatation by clonidine may be due to the abolition of the increase in parasympathetically mediated pupil constriction due to reduced LC activity
mydriatics, humans, blood pressure, physiology, adrenergic alpha-agonists, cross-over studies, blood, drug effects, double-blind method, drug synergism, adult, locus coeruleus
95-106
Hou, R.H.
470bdcbc-93a9-4dad-aac5-26d455c34376
Samuels, E.R.
be1fd344-e73a-43da-aca8-33c6e21cb7f2
Raisi, M.
cf9a9cbc-25cb-4e44-a867-c2032bf6af21
Langley, R.W.
579cc42e-972f-4422-952f-1c76ecc4b4e3
Szabadi, E.
cff688f8-264f-4ca3-a2c4-cb10930f1956
Bradshaw, C.M.
0baafd10-0e91-4113-b90b-27132bd77305
January 2006
Hou, R.H.
470bdcbc-93a9-4dad-aac5-26d455c34376
Samuels, E.R.
be1fd344-e73a-43da-aca8-33c6e21cb7f2
Raisi, M.
cf9a9cbc-25cb-4e44-a867-c2032bf6af21
Langley, R.W.
579cc42e-972f-4422-952f-1c76ecc4b4e3
Szabadi, E.
cff688f8-264f-4ca3-a2c4-cb10930f1956
Bradshaw, C.M.
0baafd10-0e91-4113-b90b-27132bd77305
Hou, R.H., Samuels, E.R., Raisi, M., Langley, R.W., Szabadi, E. and Bradshaw, C.M.
(2006)
Why patients with Alzheimer’s disease may show increased sensitivity to tropicamide eye drops: role of locus coeruleus.
Psychopharmacology, 184 (1), .
(doi:10.1007/s00213-005-0227-9).
(PMID:16308726)
Abstract
Rationale: patients suffering from Alzheimer’s disease (AD) may show increased sensitivity to tropicamide, a muscarinic cholinoceptor antagonist. AD is associated with a severe loss of noradrenergic neurones in the locus coeruleus (LC), which can be “switched off” experimentally by the ?2-adrenoceptor agonist clonidine. The possibility arises that increased pupillary sensitivity to tropicamide in AD may be due to diminished LC activity.
Objective: to examine the hypothesis that clonidine may potentiate tropicamide-evoked mydriasis.
Materials and methods: sixteen healthy male volunteers participated in two experimental sessions (0.2 mg clonidine or placebo) conducted 1 week apart. In each session tropicamide (0.01% 10 ?l×2) was applied to the left eye and artificial tear (10 ?l×2) was applied to the right eye. Pupillary functions (resting pupil diameter and light and darkness reflexes), alertness and non-pupillary autonomic functions (blood pressure, heart rate, core temperature and salivary output) were measured. Data were analysed by ANOVA, with multiple comparisons.
Results: tropicamide increased resting pupil diameter, velocity and amplitude of the darkness reflex response, and decreased recovery time of the light reflex response. Clonidine affected all these pupillary measures in the opposite direction with the exception of the recovery time. The mydriatic response to tropicamide was potentiated by pre-treatment with clonidine. Clonidine reduced critical flicker fusion frequency, subjective alertness, blood pressure, salivation and temperature.
Conclusions: the potentiation of tropicamide-evoked pupil dilatation by clonidine may be due to the abolition of the increase in parasympathetically mediated pupil constriction due to reduced LC activity
This record has no associated files available for download.
More information
Published date: January 2006
Keywords:
mydriatics, humans, blood pressure, physiology, adrenergic alpha-agonists, cross-over studies, blood, drug effects, double-blind method, drug synergism, adult, locus coeruleus
Organisations:
Clinical Neurosciences
Identifiers
Local EPrints ID: 181861
URI: http://eprints.soton.ac.uk/id/eprint/181861
ISSN: 0033-3158
PURE UUID: c4a83786-4aff-4588-8bf6-c9b0e85b4156
Catalogue record
Date deposited: 12 May 2011 13:17
Last modified: 15 Mar 2024 03:28
Export record
Altmetrics
Contributors
Author:
E.R. Samuels
Author:
M. Raisi
Author:
R.W. Langley
Author:
E. Szabadi
Author:
C.M. Bradshaw
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics